Tuberculosis remains one of humanity's most consequential infectious disease failures — a curable disease that still kills more people annually than almost any other pathogen. This landmark GBD 2023 analysis arrives at a pivotal moment: global health funding cuts are threatening TB control infrastructure precisely when sustained progress is most needed, making this comprehensive baseline assessment strategically critical for researchers, clinicians, and policymakers alike.
Spanning 204 countries and territories across more than three decades (1990–2023), the analysis quantified TB mortality, incidence, prevalence, and disability-adjusted life-years (DALYs) using an ensemble of vital registration, surveillance, verbal autopsy, and minimally invasive tissue sampling data. Crucially, the methodology stratified burden by HIV co-infection status and drug-resistance profile — including multidrug-resistant TB (MDR-TB) — using population attributable fraction approaches. Risk factor contributions from alcohol use, smoking, and elevated fasting plasma glucose were separately modeled through comparative risk assessment. Progress toward the WHO End TB Strategy targets — a 95% reduction in deaths and 90% reduction in incidence between 2015 and 2035 — was explicitly evaluated, with findings suggesting the trajectory falls significantly short of those benchmarks.
This study's strength lies in its methodological rigor and geographic granularity, but several caveats temper interpretation. Vital registration data quality varies enormously across high-burden nations, and modeled estimates carry wide uncertainty intervals in data-sparse settings. The MDR-TB stratification is particularly valuable, as drug-resistant strains represent an escalating threat that standard incidence metrics tend to obscure. From a longevity and public health standpoint, the intersection of TB with HIV and metabolic risk factors like hyperglycemia signals that TB cannot be treated as a siloed infectious disease problem — it is deeply embedded in the broader chronic disease landscape. For health-conscious adults in low-burden nations, the modifiable risk factors identified here — smoking and alcohol — reinforce familiar prevention priorities with a newly quantified global-burden dimension. This analysis is confirmatory in framing but potentially paradigm-shifting in its documentation of how far off-course the End TB trajectory currently sits.